PRESS RELEASE 
    Utah 
    Medical Products, Inc. 
    Reports Financial Performance for 
    First Quarter 2006 
    April
    19, 2006 
    Contact: Paul Richins  
    (801) 566-1200  
    Salt Lake City, Utah - Utah Medical Products, 
    Inc. (Nasdaq:UTMD) reports that all primary income statement measures of 
    financial performance in First Quarter (1Q) 2006 increased compared to 1Q 
    2005, according to the following table: 
    
      
      
        
          | Sales | 
          + 7%    
           | 
         
        
          | Gross Profits | 
          + 7% | 
         
        
          | Operating Profits | 
          + 3% | 
         
        
          | Earnings before Taxes (EBT) | 
          + 9% | 
         
        
          | Net Income | 
          + 3% | 
         
        
          | Earnings per Share (EPS) | 
          +10% | 
         
       
      
     
    The increase in operating profits was smaller 
    than the growth in sales and gross profits because of higher operating 
    expenses from 1) an increase in sales & marketing expense due primarily to 
    an expanded sales force ($89,000), 2) higher legal fees and litigation 
    expenses ($58,000) and the non-cash expense ($43,000) associated with 
    expensing unvested stock options per SFAS 123R. However, the higher 
    operating expenses ($194,000 total increase) were largely offset by higher 
    non-operating income ($160,000) from the investment of cash balances.  
     
    Net income increased less than EBT due to a higher income tax provision in 
    1Q 2006. In 2005, UTMD was allowed a temporary tax deduction on repatriated 
    foreign earnings as a result of The American Jobs Creation Act of 2004. 
    However, a lower number of diluted shares used to calculate eps, as a result 
    of share repurchases since 1Q 2005, more than compensated for the higher 
    income tax provision. Compared to 1Q 2005, diluted outstanding shares used 
    for calculating 1Q 2006 eps were down 6%. Eps for 1Q 2006 were $.50. Eps for 
    1Q 2005 were $.46. Eps for the most recent twelve months were $1.85. 
     
    In 1Q 2006, UTMD achieved a gross profit margin of 56.4% and a net profit 
    margin of 28.7%. In 1Q 2005, those respective profit margins were 56.1% and 
    29.6%. 
     
    Comparing 1Q 2006 sales to 1Q 2005 sales in product categories, neonatal 
    product sales were up 35%, obstetrics product sales were unchanged, 
    gynecology/ electrosurgery product sales were up 10% and blood pressure 
    monitoring/ components sales were down 8%. Both domestic and international 
    sales were up 7%. Although trade shipments from Ireland were up 4% in EURO 
    terms, they were down 5% in US Dollar terms because of a stronger U.S. 
    dollar.  
     
    UTMD’s balance sheet remained strong. Compared to December 31, 2005, working 
    capital increased more than $0.9 million. Stockholders’ Equity increased 
    more than 
    $1.0 million even though dividends and share repurchases, which reduce 
    Stockholders’ Equity, totaled $1.1 million. 
     
    Financial ratios which may be of interest to shareholders follow: 
    1) Current Ratio = 9.3 
    2) Days in Receivables (based on 1Q sales activity) = 44 
    3) Average Inventory Turns (based on 1Q CGS) = 3.7 
    4) Year-to-Date ROE (after payment of dividends) = 17% 
     
    UTMD's dilution from unexercised option shares 
    added to actual weighted average outstanding shares for purposes of 
    calculating eps was 117,000 in 1Q 2006 compared to 230,000 in 1Q 2005. The 
    actual number of outstanding shares at the end of 1Q 2006 was 3,966,400 
    which included 1Q employee and outside director option exercises of 266,600 
    shares and 1Q share repurchases of 12,100. The average price paid by the 
    Company to repurchase shares in the open market during 1Q 2006 was $30.67 
    including commissions. The total number of outstanding unexercised options 
    at March 31, 2006 was about 280,000 shares at an average exercise price of 
    $17.75/ share, including shares awarded but not vested. This compares to 
    728,000 option shares outstanding at the end of 1Q 2005.  
     
    Risk factors that could cause results to differ materially in future 
    quarters include market acceptance of products, timing of regulatory 
    approval of new products, regulatory intervention in current operations, the 
    Company’s ability to efficiently manufacture, market, and sell its products, 
    among other factors that have been outlined in UTMD's 
    public disclosure filings with the SEC. The SEC Form 10-Q for 1Q 2006 will 
    be filed with the SEC by May 10.  
     
    Utah Medical Products, Inc., with particular interest in health care for 
    women and their babies, develops, manufactures, assembles and markets a 
    broad range of disposable and reusable specialty medical devices designed 
    for better health outcomes for patients and their care-providers. For more 
    information about Utah Medical Products, Inc., visit UTMD's 
    website at www.utahmed.com. 
      
     | 
  
  
     
     
    Net Sales  
    Gross Profit  
    Operating Income  
    Income Before Tax  
    Net Income  
    Earnings Per Share (EPS) 
    Shares Outstanding (diluted)  | 
    
     
     
    1Q 
    2006 
    $7,104 
    4,007 
    2,632 
    3,046 
    2,036 
    $0.500 
    4,070 
       | 
    
     
    1Q 
    2005 
    $6,652 
    3,734 
    2,552 
    2,806 
    1,969 
    $0.455 
    4,326 | 
    Percent 
    Change 
    +6.8% 
    +7.3% 
    +3.1% 
    +8.6% 
    +3.4% 
    +9.9% | 
      | 
      | 
  
  
    
    
      
        |   | 
        
        (unaudited) | 
        
        (audited) | 
        
        (unaudited) | 
       
      
        |   | 
        
        MAR 
        31, 2006 | 
        
        DEC 
        31, 2005 | 
        
        MAR 31, 2005 | 
       
      
        | 
        
        Assets | 
          | 
          | 
          | 
       
      
        | 
            Cash & 
        Investments | 
        
        $  
        17,423 | 
        
        $  
        17,453 | 
        
        $     
        16,525 | 
       
      
        | 
            Accounts 
        & Other Receivables, Net | 
        
          
        4,825 | 
        
          
        4,418 | 
        
        3,916 | 
       
      
        | 
            Inventories | 
        
        3,470 | 
        
        3,305 | 
        
        2,836 | 
       
      
        | 
            Other Current Assets | 
        
        655 | 
        
        682 | 
        
        945 | 
       
      
        | 
           
             Total Current Assets | 
        
        26,373 | 
        
        25,858 | 
        
        24,222 | 
       
      
        | 
        
        Property & Equipment,
        Net | 
        
        8,258 | 
        
        8,160 | 
        
        8,774 | 
       
      
        | 
        
        Intangible Assets, Net   | 
        
        7,612 | 
        
        7,624 | 
        
        7,662 | 
       
      
        | 
                   
        Total Assets | 
        
        $ 42,243 | 
        
        $ 41,642 | 
        
        $  40,658 | 
       
      
        |   | 
          | 
          | 
          | 
       
      
        | 
        Liabilities  
        & 
        Stockholders’ Equity | 
          | 
          | 
          | 
       
      
        | 
          
              Total Current Liabilities | 
        
        $  
        2,848 | 
        
        $  
        3,175 | 
        
        $  
        3,820 | 
       
      
        | 
        Note Payable | 
        
        5,251 | 
        
        5,336 | 
        
        0 | 
       
      
        | 
        
        Deferred Income Taxes | 
        
        257 | 
        
        274 | 
        
        753 | 
       
      
        | 
        
        Stockholders’ Equity | 
        
        33,887 | 
        
        32,857 | 
        
        36,085 | 
       
      
        | 
                   
        Total Liabilities  
        & 
           | 
        
        $ 42,243 | 
        
        $ 41,642 | 
        
        $  40,658 | 
       
      
        | 
                   
        Stockholders’ Equity | 
         
     
     |